NASHUA, NH, 12 December 2017 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is now available at two California-based centers from The US Oncology Network – Santa Clarita Radiation Therapy Center and Sherman Oaks Radiation Therapy Center. Local patients with non-melanoma skin cancer (NMSC), including individuals precluded from surgery or those seeking a non-invasive option, will now have access to a proven alternative that has successfully treated more than 10,000 individuals worldwide.
“We are pleased to provide our community with the most advanced and targeted cancer care that meets the needs of each and every patient,” said Dr. May Lin Tao, Medical Director of Santa Clarita Radiation Therapy Center.
“Adding Xoft to our infrastructure expands our clinical tools which help patients achieve similar low rates of recurrence with excellent cosmetic outcomes compared to Mohs surgery – all with virtually no downtime,” said Dr. Marc Botnick, Medical Director of Sherman Oaks Radiation Therapy Center.
Ad Statistics
Times Displayed: 49670
Times Visited: 1409 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
The Xoft technology features a miniaturized, low-energy X-ray source that delivers a precise dose of targeted, isotope-free radiation directly to the lesion, reducing the risk of damage to surrounding healthy tissue. The mobile system can be easily maneuvered from room-to-room, while minimal shielding requirements enable clinicians to deliver treatment in a standard exam room, offering a highly-efficient, flexible solution.
Appropriate candidates include NMSC patients with lesions in anatomically challenging locations such as the ears, nose, scalp, neck, shin, and elbows, as well as those with wound healing challenges, individuals taking anticoagulants, and patients with medical comorbidities that may prohibit them from surgery.
“A growing body of positive clinical research underscores the valuable benefits Xoft presents to both providers and patients seeking a non-invasive treatment option – reducing practice overhead and fostering provider collaboration, while also delivering a positive and personalized patient experience,” said Ken Ferry, CEO of iCAD. “We are thrilled to partner with one of the nation’s leading radiation oncology networks to tackle the growing NMSC epidemic and provide unprecedented access to our advanced treatment option.”
The Xoft System is cleared by the U.S. Food and Drug Administration, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including NMSC, early-stage breast cancer, and gynecological cancers.
